Genprex Inc (GNPX) Actualités

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for...

Genprex to Participate in 2024 BIO Europe Conference

Genprex to Participate in 2024 BIO Europe Conference PR Newswire AUSTIN, Texas, Oct. 31, 2024 AUSTIN, Texas...